Searchable abstracts of presentations at key conferences in endocrinology

ea0063p235 | Pituitary and Neuroendocrinology 1 | ECE2019

No central adrenal insufficiency found in adults with prader-willi syndrome tested by multiple dose metyrapone test

Rosenberg Anna , Pellikaan Karlijn , Davidse Kirsten , Donze Stephany , Hokken-Koelega Anita , de Graaff Laura

Introduction: Individuals with Prader-Willi syndrome (PWS) have hypothalamic dysfunction, with deficiencies of several hypothalamic-pituitary axes. Prevalence of central hypogonadism, hypothyroidism and growth hormone deficiency are increased in comparison with non-PWS individuals. Central adrenal insufficiency (CAI) has also been reported in PWS. Several studies, using different testing modalities, have reported strikingly differing prevalences of CAI in PWS, ranging from 0% ...

ea0063gp175 | Obesity (1) | ECE2019

Normal IGF-bioactivity and low free IGF-I in patients with Prader-Willi syndrome with high total serum IGF-I: immunoreactive IGF-I concentrations poorly reflect IGF bio-activity and bio-availability

Pellikaan Karlijn , Elizabeth Melitza , Donze Stephany , van den Berg Sjoerd , van Doorn Jaap , Peeters Robin P , Hokken-Koelega Anita CS , de Graaff Laura CG

Introduction: Prader-Willi Syndrome (PWS) is a complex syndrome including hyperphagia, pituitary hormone deficiencies, low muscle mass and cognitive impairment. Treatment with recombinant Growth Hormone (GH) has beneficial effects on body composition, physical performance, cognition, psychomotor development, respiratory function, and quality of life of patients with PWS. GH treatment has a narrow therapeutic range. Clinicians measure serum immunoreactive Insulin-like Growth Fa...